Cell-based therapies of liver diseases: age-related challenges

Konstantin N Yarygin, Alexei Y Lupatov, Irina V Kholodenko Laboratory of Cell Biology, Institute of Biomedical Chemistry, Moscow, Russia Abstract: The scope of this review is to revise recent advances of the cell-based therapies of liver diseases with an emphasis on cell donor’s and pati...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yarygin KN, Lupatov AY, Kholodenko IV
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	cell aging rejuvenation liver engineering liver cell therapy Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/9ff190b344d24645a06bd67a4fd2fc50
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9ff190b344d24645a06bd67a4fd2fc50
record_format	dspace
spelling	oai:doaj.org-article:9ff190b344d24645a06bd67a4fd2fc502021-12-02T01:38:42ZCell-based therapies of liver diseases: age-related challenges1178-1998https://doaj.org/article/9ff190b344d24645a06bd67a4fd2fc502015-12-01T00:00:00Zhttps://www.dovepress.com/cell-based-therapies-of-liver-diseases-age-related-challenges-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Konstantin N Yarygin, Alexei Y Lupatov, Irina V Kholodenko Laboratory of Cell Biology, Institute of Biomedical Chemistry, Moscow, Russia Abstract: The scope of this review is to revise recent advances of the cell-based therapies of liver diseases with an emphasis on cell donor’s and patient’s age. Regenerative medicine with cell-based technologies as its integral part is focused on the structural and functional restoration of tissues impaired by sickness or aging. Unlike drug-based medicine directed primarily at alleviation of symptoms, regenerative medicine offers a more holistic approach to disease and senescence management aimed to achieve restoration of homeostasis. Hepatocyte transplantation and organ engineering are very probable forthcoming options of liver disease treatment in people of different ages and vigorous research and technological innovations in this area are in progress. Accordingly, availability of sufficient amounts of functional human hepatocytes is crucial. Direct isolation of autologous hepatocytes from liver biopsy is problematic due to related discomfort and difficulties with further expansion of cells, particularly those derived from aging people. Allogeneic primary human hepatocytes meeting quality standards are also in short supply. Alternatively, autologous hepatocytes can be produced by reprogramming of differentiated cells through the stage of induced pluripotent stem cells. In addition, fibroblasts and mesenchymal stromal cells can be directly induced to undergo advanced stage hepatogenic differentiation. Reprogramming of cells derived from elderly people is accompanied by the reversal of age-associated changes at the cellular level manifesting itself by telomere elongation and the U-turn of DNA methylation. Cell reprogramming can provide high quality rejuvenated hepatocytes for cell therapy and liver tissue engineering. Further technological advancements and establishment of national and global registries of induced pluripotent stem cell lines homozygous for HLA haplotypes can allow industry-style production of livers for immunosuppression-free transplantation. Keywords: cell aging, rejuvenation, liver engineering, liver cell therapyYarygin KNLupatov AYKholodenko IVDove Medical Pressarticlecell agingrejuvenationliver engineeringliver cell therapyGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 10, Pp 1909-1924 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	cell aging rejuvenation liver engineering liver cell therapy Geriatrics RC952-954.6
spellingShingle	cell aging rejuvenation liver engineering liver cell therapy Geriatrics RC952-954.6 Yarygin KN Lupatov AY Kholodenko IV Cell-based therapies of liver diseases: age-related challenges
description	Konstantin N Yarygin, Alexei Y Lupatov, Irina V Kholodenko Laboratory of Cell Biology, Institute of Biomedical Chemistry, Moscow, Russia Abstract: The scope of this review is to revise recent advances of the cell-based therapies of liver diseases with an emphasis on cell donor’s and patient’s age. Regenerative medicine with cell-based technologies as its integral part is focused on the structural and functional restoration of tissues impaired by sickness or aging. Unlike drug-based medicine directed primarily at alleviation of symptoms, regenerative medicine offers a more holistic approach to disease and senescence management aimed to achieve restoration of homeostasis. Hepatocyte transplantation and organ engineering are very probable forthcoming options of liver disease treatment in people of different ages and vigorous research and technological innovations in this area are in progress. Accordingly, availability of sufficient amounts of functional human hepatocytes is crucial. Direct isolation of autologous hepatocytes from liver biopsy is problematic due to related discomfort and difficulties with further expansion of cells, particularly those derived from aging people. Allogeneic primary human hepatocytes meeting quality standards are also in short supply. Alternatively, autologous hepatocytes can be produced by reprogramming of differentiated cells through the stage of induced pluripotent stem cells. In addition, fibroblasts and mesenchymal stromal cells can be directly induced to undergo advanced stage hepatogenic differentiation. Reprogramming of cells derived from elderly people is accompanied by the reversal of age-associated changes at the cellular level manifesting itself by telomere elongation and the U-turn of DNA methylation. Cell reprogramming can provide high quality rejuvenated hepatocytes for cell therapy and liver tissue engineering. Further technological advancements and establishment of national and global registries of induced pluripotent stem cell lines homozygous for HLA haplotypes can allow industry-style production of livers for immunosuppression-free transplantation. Keywords: cell aging, rejuvenation, liver engineering, liver cell therapy
format	article
author	Yarygin KN Lupatov AY Kholodenko IV
author_facet	Yarygin KN Lupatov AY Kholodenko IV
author_sort	Yarygin KN
title	Cell-based therapies of liver diseases: age-related challenges
title_short	Cell-based therapies of liver diseases: age-related challenges
title_full	Cell-based therapies of liver diseases: age-related challenges
title_fullStr	Cell-based therapies of liver diseases: age-related challenges
title_full_unstemmed	Cell-based therapies of liver diseases: age-related challenges
title_sort	cell-based therapies of liver diseases: age-related challenges
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/9ff190b344d24645a06bd67a4fd2fc50
work_keys_str_mv	AT yaryginkn cellbasedtherapiesofliverdiseasesagerelatedchallenges AT lupatovay cellbasedtherapiesofliverdiseasesagerelatedchallenges AT kholodenkoiv cellbasedtherapiesofliverdiseasesagerelatedchallenges
_version_	1718402975923175424

Cell-based therapies of liver diseases: age-related challenges

Ejemplares similares